Literature DB >> 201668

Properties of the plasma very low and low density lipoproteins in Tangier disease.

R J Heinen, P N Herbert, D S Fredrickson.   

Abstract

The absence of normal high density lipoproteins (HDL) in Tangier disease is well established, but the properties of very low density lipoproteins (VLDL) and low density lipoproteins (LDL) in this disorder have not been well defined. The profiles obtained by analytic ultracentrifugation and the chemical composition, morphology, and electrophoretic mobility of Tangier and normal VLDL and LDL were compared. Apolipoproteins were fractionated by gel chromatography and characterized by amino acid analysis, polyacrylamide-gel electrophoresis, and immunochemical reactivity. Concentrations of low density lipoproteins of S(f) (o) 0-12 were reduced in three of six Tangier plasmas studied by analytic ultracentrifugation. Accumulation of intermediate density lipoproteins (S(f) (o) 12-20) was not observed. Two subjects with hypertriglyceridemia had normal VLDL (S(f) (o) 20-400) levels, suggesting that abnormalities of chylomicron metabolism probably account for the hypertriglyceridemia frequently observed in this disorder. Tangier VLDL migrate more slowly than normal VLDL on paper electrophoresis, yet their morphology, gross chemical composition, and qualitative apolipoprotein content are similar. Quantitative abnormalities in C-apolipoproteins, however, were observed in Tangier VLDL. When patients were consuming unrestricted diets, C apoproteins accounted for 19-49% of the protein in lipoproteins of d < 1.006 g/ml. Ingestion of low-fat, high-carbohydrate diets reduced the VLDL-C-apoprotein content in all Tangier patients (mean = 17% of VLDL protein vs. 43% in controls). These findings suggested that a major proportion of the C apoproteins in Tangier plasma is associated with chylomicrons or their remnants, perhaps because the C-apoprotein reservoir normally provided by HDL is absent. This secondary mechanism for C-apoprotein conservation is lost when dietary fat is withdrawn.LDL-2 (1.035 < d < 1.063) from Tangier and control plasma had identical electrophoretic mobilities. Tangier LDL-2 had slightly smaller median diameters (210-225 A vs. 230-240 A in controls) and a quite different composition than normal LDL-2. Triglyceride accounted for a mean of 29% of Tangier LDL-2 mass (control = 6%) and the cholesteryl ester content was reduced by about 50%. Thus, HDL may be required for the generation of chemically normal LDL. Alternatively, the fundamental defect in Tangier disease may involve all lipoprotein classes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 201668      PMCID: PMC372520          DOI: 10.1172/JCI108910

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat.

Authors:  O D Mjos; O Faergeman; R L Hamilton; R J Havel
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.

Authors:  S Eisenberg; D W Bilheimer; R I Levy; F T Lindgren
Journal:  Biochim Biophys Acta       Date:  1973-12-20

Review 3.  The metabolic role of lecithin: cholesterol acyltransferase: perspectives form pathology.

Authors:  J A Glomset; K R Norum
Journal:  Adv Lipid Res       Date:  1973

4.  Fractionation of the C-apoproteins from human plasma very low density lipoproteins.

Authors:  P N Herbert; R S Shulman; R I Levy; D S Fredrickson
Journal:  J Biol Chem       Date:  1973-07-25       Impact factor: 5.157

5.  Characterization and quantitation of the apolipoproteins from human chyle chylomicrons.

Authors:  G Kostner; A Holasek
Journal:  Biochemistry       Date:  1972-03-28       Impact factor: 3.162

6.  Familial alpha-lipoprotein deficiency (Tangier disease) with neurological abnormalities.

Authors:  R S Kocen; J K Lloyd; P T Lascelles; A S Fosbrooke; D Willims
Journal:  Lancet       Date:  1967-06-24       Impact factor: 79.321

7.  Very-low-density lipoprotein in intestinal lymph: evidence for presence of the A protein.

Authors:  R K Ockner; K J Bloch; K J Isselbacher
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

8.  A specific apoprotein activator for lipoprotein lipase.

Authors:  J C LaRosa; R I Levy; P Herbert; S E Lux; D S Fredrickson
Journal:  Biochem Biophys Res Commun       Date:  1970-10-09       Impact factor: 3.575

9.  Lipid and lipoprotein measurements in a normal adult American population.

Authors:  F T Lindgren; G L Adamson; L C Jenson; P D Wood
Journal:  Lipids       Date:  1975-12       Impact factor: 1.880

10.  Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia.

Authors:  A M Gotto; W V Brown; R I Levy; M E Birnbaumer; D S Fredrickson
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

View more
  11 in total

1.  Familial high-density lipoprotein deficiency (Tangier disease): the third Italian case.

Authors:  G Bracco; G Dotti; F Levis; E David; G Saracco; M Rizzetto; G Verme
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

2.  Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Authors:  Andreas K Kateifides; Irina N Gorshkova; Adelina Duka; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2011-04-19       Impact factor: 5.922

3.  Multicompartmental analysis of cholesterol metabolism in man. Quantitative kinetic evaluation of precursor sources and turnover of high density lipoprotein cholesterol esters.

Authors:  C C Schwartz; M Berman; Z R Vlahcevic; L Swell
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

4.  Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux.

Authors:  M C Cheung; A J Mendez; A C Wolf; R H Knopp
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

5.  Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.

Authors:  Liam R Brunham; Janine K Kruit; Jahangir Iqbal; Catherine Fievet; Jenelle M Timmins; Terry D Pape; Bryan A Coburn; Nagat Bissada; Bart Staels; Albert K Groen; M Mahmood Hussain; John S Parks; Folkert Kuipers; Michael R Hayden
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

6.  Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.

Authors:  T M Forte; A V Nichols; R M Krauss; R A Norum
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

7.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier).

Authors:  L L Kay; R Ronan; E J Schaefer; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

9.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.

Authors:  K H Weisgraber; T P Bersot; R W Mahley; G Franceschini; C R Sirtori
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

10.  Postprandial hypertriglyceridaemia in patients with Tangier disease.

Authors:  G Kolovou; D Daskalova; K Anagnostopoulou; I Hoursalas; V Voudris; D P Mikhailidis; D V Cokkinos
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.